Detecting tripartite motif-containing protein 46 (TRIM46)-IgG by cell-binding assay using serum specimens
Evaluation of an autoimmune/paraneoplastic neurological syndrome among patients presenting with cerebellar ataxia, encephalitis, or encephalomyelitis.
If the indirect immunofluorescence (IFA) pattern suggests tripartite motif-containing protein 46 (TRIM46) IgG, then TRIM46 antibody cell-binding assay and IFA titer will be performed at an additional charge.
Only orderable as a reflex. For more information see:
ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum
EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum
MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum
Cell Binding Assay (CBA)
TRIM46
Tripartite Motif-Containing Protein 46
Fibronectin type III
C-terminal B-30.2-like motif
TRIFIC
If the indirect immunofluorescence (IFA) pattern suggests tripartite motif-containing protein 46 (TRIM46) IgG, then TRIM46 antibody cell-binding assay and IFA titer will be performed at an additional charge.
Serum
Only orderable as a reflex. For more information see:
ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum
EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum
MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 72 hours |
Detecting tripartite motif-containing protein 46 (TRIM46)-IgG by cell-binding assay using serum specimens
Evaluation of an autoimmune/paraneoplastic neurological syndrome among patients presenting with cerebellar ataxia, encephalitis, or encephalomyelitis.
If the indirect immunofluorescence (IFA) pattern suggests tripartite motif-containing protein 46 (TRIM46) IgG, then TRIM46 antibody cell-binding assay and IFA titer will be performed at an additional charge.
Tripartite motif-containing protein 46 (TRIM46)-IgG is a marker of an autoimmune neurological disorder commonly associated with underlying malignancy. Patients commonly present with cerebellar ataxia and neoplasms frequently of neuroendocrine lineage.
Only orderable as a reflex. For more information see:
ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum
EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum
MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum
Negative
A positive result is consistent with a tripartite motif-containing protein 46 (TRIM46)-IgG associated autoimmune disease of the central nervous system. A paraneoplastic cause should be considered.
A negative result does not exclude the presence of neurological autoimmunity or cancer. The use of immunotherapy prior to sample collection may negatively impact the sensitivity of this assay.
1. van Coevorden-Hameete MH, van Beuningen SFB, Perrenoud M, et al. Antibodies to TRIM46 are associated with paraneoplastic neurological syndromes. Ann Clin Tran Neurol. 2017;4(9):680-686. doi:10.1002/acn3.396
2. Sham’ili S, de Leeuw B, Hulsenboom E, Jaarsma D, Smitt PS. A new paraneoplastic encephalomyelitis autoantibody reactive with the axon initial segment. Neurosci Lett. 2009;467(2):169-72. doi:10.1016/j.neulet.2009.10.031
3. Valencia-Sanchez C, Knight AM, Hammami B, et al. TRIM46 autoantibody: expanded neurological phenotype and oncological associations (1657). Neurology. 2021;96(15 Supplement)
Patient specimen is applied to a composite slide containing transfected and nontransfected HEK-293 cells. After incubation and washing, fluorescein-conjugated goat-antihuman IgG is applied to detect the presence of patient IgG binding.(Package insert: IIFT: Neurology Mosaics, Instructions for the indirect immunofluorescence test. EUROIMMUN; FA_112d-1_A_UK_C13, 02/2019)
Monday through Sunday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
86255
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
T46CS | TRIM46 Ab CBA, S | 105525-0 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
616449 | TRIM46 Ab CBA, S | 105525-0 |